SUPPLEMENTARY FILE A

Study/treatment group	***N***	***Years of inclusion***	***Study specific inclusion criteria***
Feasibility study	30	2013-2017	*Patient characteristics* Age ≥ 18 years; Karnofsky Performance Status ≥ 70; Fit for spinal anaesthesia; International Prostate Symptom Score < 15. *Tumour characteristics* Tumour location technically feasible for brachytherapy; Tumour visible MRI and PSMA/choline-PET/CT; Biopsy proven local recurrence; PSA level ≤ 10 ng/mL; PSA doubling time (PSADT) ≥ 12 months; Tumour stage (MRI) ≤ T2c; Recurrence ≥ 2 years after primary radiotherapy; No lymph node and/or distant metastases.
PRECISE study	42	2018-2019	*Patient characteristics* See 'Feasibility study'. *Tumour characteristics* Tumour location technically feasible for brachytherapy; Concordance between PSMA-PET/CT and mp-MRI; PSA level ≤2 0 ng/mL; PSA doubling time (PSADT) ≥ 9 months; Tumour stage (MRI) ≤ T3b; Recurrence ≥ 2 years after primary radiotherapy; No lymph node and/or distant metastases.
Non-study	78	2015-2020	*Patient characteristics* See 'Feasibility study'. *Tumour characteristics* No specific criteria (i.e., those not eligible for treatment within either the feasibility of the PRECISE study, for example due to higher pre-salvage PSA and/or shorter PSA doubling time).